| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in IONS over the last quarter tilts toward selling: insiders offloaded a net 1,410 shares worth roughly $61K. In the past 30 days, 0 insiders bought and 2 sold.
Both insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 242.8K | $9.68M | - | |
| Dir | 161.2K | $6.43M | - | |
| VP | 102.9K | $4.10M | - | |
| CFO | 82.7K | $3.30M | - | |
| VP | 77.1K | $3.08M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Joseph Baroldi65 | EVP, Chief Business Officer | Sale+OE10b5-1 | 250 | $62.00 | $15,500.00 | -0.8% | +33.6% | -5.1% | |
| Sep 3, 2025 | Joseph Baroldi65 | EVP, Chief Business Officer | Sale+OE10b5-1 | 32,800 | $59.34 | $1,946,220.28 | -66.0% | +34.4% | -3.9% | |
| Sep 3, 2025 | Shannon L. Devers64 | EVP, Chief Human Resources Ofc | Sale+OE10b5-1 | 3,162 | $61.02 | $192,942.71 | -17.4% | +34.4% | -3.9% | |
| Sep 3, 2025 | Joseph Klein III62 | Director | Sale+OE10b5-1 | 28,000 | $60.00 | $1,680,000.00 | - | +34.4% | -3.9% | |
| Sep 3, 2025 | Brett P Monia63 | Chief Executive Officer | Sale+OE | 203,814 | $60.32 | $12,294,703.00 | -53.1% | +34.4% | -3.9% | |
| Sep 3, 2025 | Joseph Klein III62 | Director | Sale+OE10b5-1 | 28,000 | $60.00 | $1,680,000.00 | - | +34.4% | -3.9% | |
| Sep 3, 2025 | Eugene Schneider63 | EVP, Chf Clinical Develop Officer | Sale+OE10b5-1 | 19,658 | $60.81 | $1,195,420.87 | -27.6% | +34.4% | -3.9% | |
| Sep 3, 2025 | Joseph Loscalzo55 | Director | Sale+OE | 16,000 | $60.15 | $962,371.20 | -30.6% | +34.4% | -3.9% | |
| Sep 3, 2025 | C Frank Bennett64 | EVP, Chief Scientific Officer | Sale+OE10b5-1 | 38,909 | $59.14 | $2,301,263.58 | -27.7% | +34.4% | -3.9% | |
| Sep 3, 2025 | Patrick R. O'Neil63 | EVP CLO & General Counsel | Sale+OE10b5-1 | 89,900 | $60.03 | $5,396,843.39 | -92.5% | +34.4% | -3.9% |